Swedish Orphan Biovitrum and Biomodels to develop assay for mucositis risk in cancer treatment

14-May-2010 - Sweden

Swedish Orphan Biovitrum and Biomodels LLC announced a research agreement, under which Biomodels will explore the possibility of developing a clinically applicable screening platform that will define mucositis risk among patients undergoing conditioning regimens for hematopoietic stem cell transplants (HSCT). Swedish Orphan Biovitrum will provide funding for the project.

Oral mucositis is a frequent, painful, and debilitating complication of conditioning regimens associated with hematopoietic stem cell transplants (HSCT). The symptoms associated with mucositis are thus considerable and result in significant morbidity as well as increased health care costs. An assay which effectively determines the at-risk patient population for mucositis intervention associated with HSCT is highly desirable. From the perspective of the patients, payers, hospitals, and clinicians a personalized approach to the treatment is a great advantage.

"Swedish Orphan Biovitrum is dedicated to developing, and providing medicines for rare diseases to help people with large medical needs to better lives. The development of assays that enables a personalized medicine approach fits exactly with this mission. We are thus pleased to work with Biomodels, a company well-known for its innovative research in the areas of cancer and cancer supportive care", said Peter Edman, Chief Scientific Officer at Swedish Orphan Biovitrum

Dr. Stephen T. Sonis, Biomodels' Chief Medical; Officer, commented: "We are enormously excited to work with Swedish Orphan Biovitrum to apply our novel approach for patients undergoing aggressive cancer therapy. We are optimistic that as a consequence of this project, patients undergoing hematopoietic stem cell transplant will be able to receive targeted therapies to reduce the burden of these symptoms."

https://www.bionity.com/en/news/117549/swedish-orphan-biovitrum-and-biomodels-to-develop-assay-for-mucositis-risk-in-cancer-treatment.html